Pradefovir Mesylate

甲磺酸普雷福韦

Report date: 2025/03/31 10:42:40
NME

Base Information

Drug NamePradefovir Mesylate
Drug Alias NameRemofovir普雷福韦pradefovir普拉福韦甲磺酸普雷福韦 +[15] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionHBV DNA Polymerase inhibitors
TargetsHBV DNA Polymerase
Therapy Area/IndicationsHepatitis B, Chronic
Global Approved IndicationsHepatitis B, Chronic
Approved Indications in ChinaHepatitis B, Chronic
Original Approved Country/TerritoryMainland China
Original Approved Date2024/10/22
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMetabasis Therapeutics Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesXi'An Gelan Xintong Pharmaceutical Co Ltd
Inactive CompaniesBausch Health Americas IncXi'an Xintong Pharmaceutical Research Co Ltd
Active IndicationsHepatitis B, Chronic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG